A
Alexander B. Olawaiye
Researcher at University of Pittsburgh
Publications - 173
Citations - 5958
Alexander B. Olawaiye is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Endometrial cancer & Medicine. The author has an hindex of 33, co-authored 148 publications receiving 4628 citations. Previous affiliations of Alexander B. Olawaiye include University at Buffalo & University of Washington.
Papers
More filters
Journal ArticleDOI
Revised FIGO staging for carcinoma of the cervix uteri
Neerja Bhatla,Jonathan S. Berek,Mauricio Cuello Fredes,Lynette Denny,Seija Grénman,Kanishka Karunaratne,Sean Kehoe,Ikuo Konishi,Alexander B. Olawaiye,Jaime Prat,Rengaswamy Sankaranarayanan,Rengaswamy Sankaranarayanan,James Brierley,David G. Mutch,Denis Querleu,David Cibula,Michael A. Quinn,Hennie Botha,Lax Sigurd,Laurel W. Rice,Hee-Sug Ryu,Hextan Y.S. Ngan,Johanna Mäenpää,Andri Andrijono,Gatot Purwoto,Amita Maheshwari,Uttam D. Bafna,Marie Plante,Jayashree Natarajan +28 more
TL;DR: To revise FIGO staging of carcinoma of the cervix uteri, allowing incorporation of imaging and/or pathological findings, and clinical assessment of tumor size and disease extent.
Book ChapterDOI
Colon and Rectum
Carolyn C. Compton,David R. Byrd,Julio Garcia-Aguilar,Scott H. Kurtzman,Alexander B. Olawaiye,Mary Kay Washington +5 more
TL;DR: In the sixth edition, Stage II was subdivided into IIA and IIB on the basis of whether the primary tumor was T3N0 or T4N0, respectively, and Stage III was subdivides into IIIA, IIIB, or IIIC (any TN2M0).
Journal ArticleDOI
Endometrial cancer: A review and current management strategies: Part I
William M. Burke,William M. Burke,James W. Orr,Mario M. Leitao,E.M. Salom,Paola A. Gehrig,Alexander B. Olawaiye,Molly Brewer,D.M. Boruta,Jeanine Villella,Jeanine Villella,Thomas J. Herzog,Fadi Abu Shahin +12 more
TL;DR: The role of hormone replacement therapy in the development of endometrial carcinoma and novel targeted therapies are examined, including chemotherapy and radiation therapy alone and in combination as well as hormone therapy.
Journal ArticleDOI
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Alexi A. Wright,Kari Bohlke,Deborah K. Armstrong,Michael A. Bookman,William A. Cliby,Robert L. Coleman,Don S. Dizon,Joseph J. Kash,Larissa A. Meyer,Kathleen N. Moore,Alexander B. Olawaiye,Jessica Oldham,Ritu Salani,Dee Sparacio,William P. Tew,Ignace Vergote,Mitchell I. Edelson +16 more
TL;DR: For selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are noninferior to primary cytoreductive and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality.